<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a prospective open trial, the effect of pulse <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> or <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> in the treatment of <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease <z:hpo ids='HP_0000554'>uveitis</z:hpo> was studied </plain></SENT>
<SENT sid="1" pm="."><plain>The therapeutic effect was evaluated based on two scores: one evolutive, reflecting <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> and calculated for each eye before and after therapy; and the other, a measure of disease severity, which took into consideration the irreversible damage </plain></SENT>
<SENT sid="2" pm="."><plain>Patients who received <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> pulse therapy (n = 8) had significantly lower evolutive scores (16.12 +/- 3.95, vs 10.37 +/- 8.53, p &lt; 0.01) than the patients receiving classical <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> pulse therapy (n = 20), who had no significant changes in their evolutive scores (12.95 +/- 8.55, vs 10.05 +/- 8.56, p &gt; 0.05) </plain></SENT>
</text></document>